6 June 2023 in IEEE Access
Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer associated with an early age of onset, greater propensity towards metastasis, and poorer clinical outcomes. It accounts for 10% to 20% of newly diagnosed breast cancer cases and disproportionately affects individuals from the African American race. While TNBC is sensitive to chemotherapy, it is also prone to relapse. This is because chemotherapy successfully targets the primary TNBC tumor cell but often fails to target the subpopulation of TNBC stem cells. TNBC stem cells display cancerous traits such as cell cycle progression, survival, proliferation, apoptosis inhibition, and epithelial-mesenchymal transition. To study the cancer initiating behavior of the TNBC stem cells, we studied their underlying signaling pathways using Boolean networks(BN). BNs are effective in capturing the causal interactions taking place in signaling pathways. We built the BN from the pathway literature and used it to evaluate the efficacies of eleven targeted inhibitory drugs in suppressing cancer-promoting genes. We simulated the BN when the pathways had single or multiple mutations, with a maximum of three mutations at a time. Our findings indicated that STAT3 , GLI , and NF-κB are the most optimal targets for inhibition. These genes are known regulators of the cancer-promoting genes in the pathway,hence our model agrees with the existing biological literature. Therefore inhibiting these three genes has the potential to prevent TNBC relapse. Additionally, our studies found that drug efficacies decreased as mutations increased in the pathway. Furthermore, we noticed that combinations of drugs performed better than single drugs.
13 January 2026 in Computational Biology and Chemistry
Prostate cancer is one of the most common cancers among men in the United States and is a leading cause of cancer-related deaths and the second most common cancer in men worldwide. In this study, we used a Boolean network model to analyze prostate cancer signaling pathways and to identify optimal drug combinations for precision therapy. By integrating publicly available biological signaling pathway data with recent research findings, we developed a comprehensive model that represents protein-protein interactions, gene mutations, and pathway dysregulation. Faults induced by mutations were modeled using the "stuck at 0" or "stuck at 1" fault paradigms, capturing the impact of genetic alterations on pathway behavior. The model was simulated across various drug combinations to determine which therapies could most effectively alleviate the aberrant signaling caused by specific mutations. To quantify therapeutic efficacy, we calculated a Size Difference (SD) score, a metric analogous to Hamming distance, measuring the deviation from normal, for each drug combination and fault scenario. The results revealed that drug combinations involving Berberine, Docetaxel, Olaparib, and Enzalutamide showed promising prediction efficacy (more than 90 %), indicating higher therapeutic potential. A distinguishing feature of this work is that, in addition to the standard prostate cancer drugs, we have included Berberine, a non-toxic natural compound with beneficial effects. These computational findings provide a framework for future experimental and clinical validation, which is necessary to confirm the therapeutic relevance of the predicted drug combinations.
7 July 2025 in IEEE Access
Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer-related deaths, often characterized by complex mutational landscapes and resistance to monotherapies. To address this, we developed a novel Boolean network (BN) model that integrates oncogenic and immunotherapy signaling pathways to evaluate the efficacy of FDA-approved drug combinations in NSCLC. This computational framework simulates the behavior of key cancer-related pathways under single and multiple mutation scenarios, offering a system-level understanding of drug response. Our model incorporates sixteen targeted inhibitors and simulates their effects on proliferation-promoting and apoptosis-regulating genes. Drug efficacy was quantitatively assessed using a normalized mean size difference (NMSD) metric. Unlike prior models that examine targeted therapy or immunotherapy in isolation, our integrated approach enables systematic evaluation of synergistic effects between these modalities. Key results show that the inclusion of immunotherapy—particularly PD-L1 inhibitors such as Durvalumab—significantly improves therapeutic outcomes, especially in networks with multiple co-occurring mutations. The most effective four-drug combination identified (Durvalumab + Lumakras + Ribociclib + Capivasertib) targets immune evasion, KRAS signaling, cell cycle regulation, and AKT activation, reducing tumor-promoting signals by 89.2% compared to the untreated state. This study provides a theoretical and mechanistic basis for combining immune checkpoint blockade with targeted therapies in NSCLC and demonstrates the utility of BN modeling in optimizing personalized, mutation-specific treatment strategies.
5 March 2026 in SSRN Electronic Journal
Osteosarcoma is a malignant bone cancer, that is common in children and pet dogs, presenting a similar genetic signature in both species. STAT3 inhibitors like Cyptotanshinone have yielded promising results in inducing cell death in a number of cancers and could be a strong candidate to attack tumor-initiating OS cells. We use Boolean network modelling to identify the theoretically most effective drug combinations for OS therapy and validate their efficacy on OS tumors grown on the back of mice. Cryptotanshinone in combination with STAT3 inhibitors was the most effective against primary OS tumors in both species. However, the same drug combinations had limited success in countering metastasis of OS cells to the lungs of the mice. Given the genomic instability of OS cells, drug combinations targeted on primary tumor mutations are not suitable to mitigate metastasis. The effects of Cryptotanshinone and other STAT3 inhibitors on metastasized OS cells require further investigation.